MarketPulse

reproxalap

24 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Aldeyra Faces Class Action Over Reproxalap Trial Data Inconsistencies

Class action lawsuit filed against Aldeyra Therapeutics alleging false statements regarding reproxalap clinical trial results. Investors from Nov 2023-Mar 2026 may be eligible.
ALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Aldeyra Therapeutics Faces Securities Lawsuit Over Trial Data Misrepresentations

Rosen Law Firm sues $ALDX over allegedly false reproxalap trial claims. Investors eligible for compensation; lead plaintiff deadline May 29, 2026.
ALDXsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Kirby Mcinerney Llp

Aldeyra Plunges 71% on Failed Trial Disclosure; Securities Lawsuit Deadline Looms

Aldeyra Therapeutics faces federal securities lawsuit alleging inadequate disclosure of failed clinical trial results for reproxalap. Stock crashed 71% after FDA rejection; investor deadline May 29, 2026.
ALDXsecurities class actionstock price decline
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Aldeyra Investors Face May 29 Deadline in Securities Fraud Suit Over Clinical Trial Claims

Rosen Law Firm urges $ALDX investors to act before May 29, 2026 deadline in securities class action alleging false reproxalap trial disclosures.
ALDXsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Aldeyra Therapeutics Hit with Class Action Over Reproxalap Trial Data Misstatements

Class action lawsuit filed against $ALDYA alleging false statements about reproxalap clinical trial results. Claims inconsistent data, unreliable findings.
ALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Aldeyra Therapeutics Faces Securities Class Action Over Clinical Trial Disclosures

Rosen Law Firm seeks lead plaintiffs in securities class action against Aldeyra Therapeutics over alleged reproxalap trial misstatements. Deadline: May 29, 2026.
ALDXsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Aldeyra Therapeutics Faces Class Action Over Reproxalap Drug Claims

Schall Law Firm seeks $ALDX investors for securities fraud lawsuit alleging Aldeyra Therapeutics made false reproxalap drug claims between November 2023-March 2026.
ALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Aldeyra Therapeutics Faces Class Action Over Reproxalap Trial Disclosures

Class action lawsuit filed against Aldeyra Therapeutics alleging false statements about reproxalap clinical trial results, covering investors from November 2023 through March 2026.
ALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Aldeyra Securities Suit Eyes May Deadline as Trial Lawyers Urge Investors to Act

Rosen Law Firm reminds $ALDX investors of May 29, 2026 deadline to join securities class action alleging false reproxalap trial disclosures.
ALDXsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Aldeyra Therapeutics Hit With Class Action Over Reproxalap Trial Misstatements

Class action lawsuit filed against Aldeyra Therapeutics for allegedly false statements on reproxalap trial results, covering investors from November 2023 to March 2026.
ALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky, Llp

Aldeyra Therapeutics Faces Securities Fraud Suit Over Hidden Trial Data Inconsistencies

Aldeyra Therapeutics faces securities fraud lawsuit alleging it concealed reproxalap trial data inconsistencies, leading to 70.7% stock collapse after FDA rejection in March 2026.
ALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Aldeyra Therapeutics Faces Class Action Over Reproxalap Drug Claims

Schall Law Firm mobilizes class action against Aldeyra Therapeutics for alleged securities fraud tied to reproxalap drug claims. Eligible investors must participate by May 29, 2026.
ALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Aldeyra Therapeutics Faces Securities Lawsuit Over Reproxalap Trial Claims

Rosen Law Firm sues Aldeyra Therapeutics for false reproxalap trial claims. Lead plaintiff deadline: May 29, 2026.
ALDXsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Aldeyra Faces Class Action Over Reproxalap Trial Data Misstatements

Class action filed against $ALDYA alleging false statements about reproxalap trial results. Eligible investors covered Nov 2023-Mar 2026.
ALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky, Llp

Aldeyra Faces Securities Fraud Suit Over Hidden Trial Data as Stock Plummets 71%

Aldeyra Therapeutics faces securities fraud lawsuit alleging hidden trial data; stock collapsed 71% after FDA's adverse decision on reproxalap.
ALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Llp

Aldeyra Therapeutics Hit with Class Action Over Failed Drug; Stock Plummets 70%

Robbins LLP sued Aldeyra Therapeutics over alleged investor misrepresentation regarding failed drug reproxalap. FDA rejected approval; stock fell 70.7%. Lead plaintiff deadline: May 29, 2026.
ALDXclass action lawsuitlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Aldeyra Faces Securities Lawsuit Over Reproxalap Trial Data; May 29 Deadline Looms

Rosen Law Firm files class action against $ALDX over allegedly misleading reproxalap clinical trial statements. Lead plaintiff deadline: May 29, 2026.
ALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Aldeyra Therapeutics Faces Securities Fraud Class Action Over Reproxalap Claims

Schall Law Firm launches class action against $ALDX over alleged false statements regarding reproxalap drug candidate. Investors who bought securities Nov 2023-Mar 2026 can join before May 29 deadline.
ALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Aldeyra Therapeutics Faces Securities Class Action Over Reproxalap Trial Disclosures

Rosen Law Firm files securities class action against $ALDX over alleged misleading statements regarding reproxalap clinical trial results. Lead plaintiff deadline set for May 29, 2026.
ALDXsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Aldeyra Faces Class Action Over Reproxalap Trial Claims; Investors Urged to Join Suit

Class action filed against Aldeyra Therapeutics alleging false reproxalap trial data claims; investors from Nov 2023-Mar 2026 may be eligible.
ALDXsecurities fraudclass action lawsuit